Abbott Laboratories Stock Forecast for 2022 - 2025 - 2030
Updated on 09/26/2022
Abbott Laboratories Stock Forecast and Price Target
Abbott Laboratories's stock price reaches the average target of $126.00 by 2023 as expected recently by nineteen notable experts, there would be a potential upside of approximately 26.2% from the last closing price in September, 2022. This possible increase is based on a high estimate of $150.00 and a low estimate of $95.00. If you are interested in ABT stock, it is important to also consider its competitors.
26.20% Upside
Abbott Laboratories Fair Value Forecast for 2022 - 2025 - 2030
In the last three years, Abbott Laboratories's Price has grown by 80.90%, rising from $75.77 to $137.08. For the following year, the 22 analysts predict that Abbott Laboratories's Fair Value will drop by 6.72%, reaching $127.87. Over the next nine years, experts predict that Abbott Laboratories's Fair Value will grow at a rate of 76.59%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$307.50 | Buy/Sell | $333.19 | 13.82% |
| DHR Stock Forecast | Danaher | Outperform |
16
|
$262.66 | Buy/Sell | $321.60 | 23.73% |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
18
|
£99.33 | Buy/Sell | £136.08 | 43.33% |
| CSL Stock Forecast | CSL | Outperform |
16
|
$284.81 | Buy/Sell | $228.01 | -22.67% |
| AMAT Stock Forecast | Applied Materials | Outperform |
10
|
$82.94 | Buy/Sell | $135.22 | 50.71% |
Abbott Laboratories Revenue Forecast for 2022 - 2025 - 2030
In the last three years, Abbott Laboratories's Revenue has grown by 40.87%, rising from $30.58B to $43.08B. For the following year, the 20 analysts predict that Abbott Laboratories's Revenue will drop by 3.35%, reaching $41.63B. Over the next nine years, experts predict that Abbott Laboratories's Revenue will grow at a rate of 43.62%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BDX Stock Forecast | Becton, Dickinson and | Outperform |
17
|
$231.64 | Buy/Sell | $278.08 | 20.88% |
| MMM Stock Forecast | 3M | Hold |
16
|
$113.00 | Buy/Sell | $147.79 | 21.24% |
| CL Stock Forecast | Colgate-Palmolive | Outperform |
18
|
$75.00 | Buy/Sell | $82.26 | 9.33% |
.jpg)
Abbott Laboratories Dividend per Share Forecast for 2022 - 2025 - 2030
In the last three years, Abbott Laboratories's Dividend per Share has grown, rising from $1.16 to $1.82 – a growth of 56.90%. In the following year, the 10 analysts surveyed believe that Abbott Laboratories's Dividend per Share will decrease by 0.55%, reaching $1.81. For the next nine years, the forecast is for Dividend per Share to grow by 128.26%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GSK Stock Forecast | GSK | Outperform |
16
|
£13.25 | Buy/Sell | £16.08 | 43.02% |
| BSX Stock Forecast | Boston Scientific | Buy |
15
|
$38.36 | Buy/Sell | $49.85 | 25.13% |
| 4568 Stock Forecast | Daiichi Sankyo Company | Outperform |
18
|
¥4.00k | Buy/Sell | ¥0.00 | 17.65% |
Abbott Laboratories Free Cash Flow Forecast for 2022 - 2025 - 2030
Abbott Laboratories's Free Cash Flow has seen impressive growth In the last three years, rising from $4.91B to $8.65B – a growth of 76.27%. In the next year, analysts believe that Free Cash Flow will reach $9.29B – an increase of 7.42%. For the next nine years, the forecast is for Free Cash Flow to grow by 24.85%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| EW Stock Forecast | Edwards Lifesciences | Outperform |
15
|
$83.59 | Buy/Sell | $127.85 | 41.76% |
| GIS Stock Forecast | General Mills | Hold |
16
|
$78.66 | Buy/Sell | $76.67 | -2.11% |
| BAYN Stock Forecast | Bayer | Outperform |
7
|
48.37€ | Buy/Sell | 67.79€ | 64.36% |
Abbott Laboratories Net Income Forecast for 2022 - 2025 - 2030
Abbott Laboratories's Net Income has grown In the last three years, rising from $2.37B to $7.07B – a growth of 198.61%. In the next year, analysts believe that Net Income will reach $8.64B – an increase of 22.21%. For the next nine years, experts predict that Abbott Laboratories's Net Income will grow at a rate of 131.06%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| EDF Stock Forecast | Electricité de France | Outperform |
17
|
11.89€ | Buy/Sell | 14.68€ | 0.93% |
| A Stock Forecast | Agilent Technologies | Outperform |
17
|
$122.31 | Buy/Sell | $149.56 | 22.64% |
| DXCM Stock Forecast | DexCom | Buy |
16
|
$80.35 | Buy/Sell | $120.89 | 24.46% |
Abbott Laboratories EBITDA Forecast for 2022 - 2025 - 2030
In the last three years, Abbott Laboratories's EBITDA has grown by 79.26%, rising from $7.12B to $12.76B. For the next year, 8 analysts project Abbott Laboratories's EBITDA to drop by 5.94%, reaching $12.00B. Over the next nine years, experts believe that Abbott Laboratories's EBITDA will grow at a rate of 43.22%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BN Stock Forecast | Danone | Hold |
18
|
48.61€ | Buy/Sell | 62.59€ | 19.32% |
| BAX Stock Forecast | Baxter International | Outperform |
17
|
$54.91 | Buy/Sell | $69.92 | 25.66% |
| 4503 Stock Forecast | Astellas Pharma | Outperform |
18
|
¥1.89k | Buy/Sell | ¥0.00 | 27.05% |
Abbott Laboratories EBIT Forecast for 2022 - 2025 - 2030
In the last three years, Abbott Laboratories's EBIT has grown, moving from $3.84B to $9.22B – an increase of 140.18%. In the next year, analysts predict that EBIT will jump to $10.33B – up 12.07% from the current level. Looking ahead to nine years, experts forecast that EBIT will grow by 112.71%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 7751 Stock Forecast | Canon | Hold |
18
|
¥3.20k | Buy/Sell | ¥0.00 | 4.65% |
| CHD Stock Forecast | Church & Dwight | Hold |
11
|
$75.26 | Buy/Sell | $90.41 | 18.39% |
| CAH Stock Forecast | Cardinal Health | Hold |
13
|
$65.77 | Buy/Sell | $58.69 | 3.39% |
Abbott Laboratories EPS Price Prediction Forecast for 2022 - 2025 - 2030
In the last three years, Abbott Laboratories's EPS has grown by 80.90%, rising from $2.88 to $5.21. For the following year, the 22 analysts predict that Abbott Laboratories's EPS will drop by 6.72%, reaching $4.86. Over the next nine years, experts predict that Abbott Laboratories's EPS will grow at a rate of 76.59%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BIO Stock Forecast | Bio-Rad Laboratories | Buy |
16
|
$414.52 | Buy/Sell | $701.33 | 68.87% |
| TECH Stock Forecast | Bio-Techne | Outperform |
16
|
$290.08 | Buy/Sell | $485.91 | 65.47% |
| 4523 Stock Forecast | Eisai | Hold |
18
|
¥5.73k | Buy/Sell | ¥0.00 | 15.12% |
Site Navigation
.jpg)